-
In 2022, the medical device industry will continue to grow rapidly, and the operating income is expected to reach 1.3 trillion yuan
Time of Update: 2023-02-01
Analysts pointed out that benefiting from the development of the economic level, the health demand is increasing, and China's medical device market has ushered in huge development opportunities. Thro
-
In the past 5 trading days, 120 listed companies have been investigated by institutions! 14 pharmaceutical companies, including Dirui Medical, were investigated
Time of Update: 2023-02-01
Seven pharmaceutical stocks rose, focusing on traditional Chinese medicine, medical devices and other tracks In the secondary market, among the 14 pharmaceutical stocks surveyed by institutions in the past 5 trading days, a total of 7 stocks rose, including Haixiang Pharmaceutical, Winbond Health, Watson Biotechnology, Heavy Drug Holdings, Zhenbao Island, Rhein Biotechnology, Beikang, Dirui Medical, etc.
-
Letter soliciting comments on the draft general rules and supporting general testing methods for plastic containers and components for pharmaceutical packaging under the Chinese Pharmacopoeia (first batch).
Time of Update: 2023-02-01
Source: National Pharmacopoeia Commission Time: 2023-01-16 10:43:54 Print Related: According to the work plan, our committee organized and drafted 5 general rules related to plastic containers and components for pharmaceutical packaging and 9 draft supporting general testing methods (see Annex 1-6), and is now soliciting relevant opinions on the draft standard.
-
In 2023, the scale of China's pharmaceutical packaging market will exceed 150 billion, and domestic leading enterprises will attract investors' attention
Time of Update: 2023-02-01
Domestic head enterprises attract the attention of investors At present, in the context of the continuous expansion of the domestic pharmaceutical packaging market, the industry believes that domestic pharmaceutical packaging material companies are also expected to usher in development opportunities and accelerate the pace of domestic substitution.
-
In 2023, the pace of mergers and acquisitions by multinational pharmaceutical companies may accelerate, targeting two hundred billion US dollar markets
Time of Update: 2023-02-01
Looking back on 2022, although the popularity of acquisitions in the pharmaceutical industry has decreased compared with the previous year, it is still remarkable. According to the 2022 pharmaceutica
-
R&D investment continues to increase, and the modernization of Chinese medicine is accelerating
Time of Update: 2023-02-01
In addition, in recent years, Yiling Pharmaceutical is also making full use of the methods and means of modern science and technology to continuously increase investment in scientific research and leapfrog development of innovative Chinese medicine drugs on the basis of inheriting and carrying forward the advantages and characteristics of traditional Chinese medicine.
-
A number of pharmaceutical companies have achieved good results, and Huahai Pharmaceutical's net profit has doubled
Time of Update: 2023-02-01
Jiudian Pharmaceutical also released a performance forecast on the evening of January 15, saying that it is expected that the net profit attributable to shareholders of listed companies in 2022 will be 263 million yuan ~ 273 million yuan, a year-on-year increase of 28.
-
After the implementation of "Class B and B tube", what is the situation of severe treatment nationwide?
Time of Update: 2023-02-01
Good medical treatment is the key to responding to the epidemic after the implementation of "Class B and B tube". By optimizing processes, expanding resources, and increasing strength, China has stre
-
Recently, there has been good news in the field of anti-tumor drugs, involving clinical and marketing...
Time of Update: 2023-02-01
The company's cyclophosphamide capsules (25mg) were included in the priority review and approval process in October 2021, and the approval of both specifications (25mg and 50mg) is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs.
-
The era of dental implants is coming to an end? The price of imported brands dropped to more than 100 yuan
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];On January 12, the topic of "the era of 10,000 yuan of dental implants is coming to an end" appeared on the hot search.
js?cdnversion='+~(-new Date()/36e5)];On January 12, the topic of "the era of 10,000 yuan of dental implants is coming to an end" appeared on the hot search.
-
Last year, the province added more than 50 national Class 1 new drugs, children's rare disease drugs, and first generic drugs
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];With a series of "warm government" incentives, the innovation vitality of Hubei's biomedical industry has been significantly enhanced.
js?cdnversion='+~(-new Date()/36e5)];With a series of "warm government" incentives, the innovation vitality of Hubei's biomedical industry has been significantly enhanced.
-
2022 pharmaceutical company report card: 1 company has disclosed a bright performance report, and more than 10 companies have increased their performance
Time of Update: 2023-02-01
According to the statistics of the data center of Oriental Fortune Network, as of January 11, about 20 pharmaceutical companies in the pharmaceutical industry have released 2022 performance reports and performance forecasts, of which 1 has disclosed bright performance reports, and more than 10 have increased their performance.
-
Heavy! The eighth batch of national procurement reporting documents involved 41 varieties and 181 product specifications
Time of Update: 2023-02-01
Appendix 1: Fill in the report of relevant drug procurement demand Appendix 2: The current competitive pattern of the eighth batch of centralized procurement varieties Data sources: NMPA, pharmacointelligence dataPS: The data is manually statistically collated, if there is a missing data, please understand, but also please correct in the comment area, thank you!If this article violates your rights, please contact us.
-
At the beginning of the new year, many pharmaceutical companies have begun to look forward to 2023 performance!
Time of Update: 2023-02-01
. In addition, Guizhou Sanli is expected to achieve a net profit attributable to the owner of the parent company of 196 million yuan ~ 217 million yuan in 2022, an increase of 43.
-
How can Shanghai break the shortage of elderly care talents and cope with the aging society?
Time of Update: 2023-02-01
and other special elderly people According to the survey of the Shanghai Municipal Committee of the Jiusan Society, most of the services provided by the "long-term care insurance" elderly in Shanghai are domestic care workers, who generally have a low level of knowledge and insufficient practical ability, and the content of home economics and elderly care training is difficult to cope with daily nursing work, and the service quality cannot be guaranteed.
-
In 2022, 20 FIC therapies will be approved by the FDA, covering HIV, diabetes and other indications
Time of Update: 2023-02-01
Pluvicto Novartis' Pluvicto was approved by the US FDA in March 2022 for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received taxane-based chemotherapy and androgen receptor signaling pathway inhibitors.
-
AstraZeneca's $1.8 billion acquisition! Why is Cincor just one year on the market?
Time of Update: 2023-02-01
1It has only been on the market for one yearGet market focus with Baxdrostat Founded in 2018, CinCor is a clinical-stage biopharmaceutical company based in the United States focused on developing novel therapies for refractory and uncontrolled hypertension and chronic kidney disease.
-
The Chinese market is promising, what are the localization strategies of foreign instrument companies?
Time of Update: 2023-02-01
14 pharmaceutical companies, including Dirui Medical, were investigated [ News Search ] [ Add to favorites ] [ Tell a friend ] [ Print this article ] [ Close Window ] Similar information January 7, 2022, Agilent announced that it will expand production and capabilities at its Shanghai manufacturing center, invest in expanding production of advanced technology products such as liquid chromatograph (LC), spectrometer, and mass spectrometer (MS) systems, and further enhance Agilent's manufacturing capabilities in China.
-
National Bureau of Statistics: Hog prices fell 10.7% month-on-month in early January
Time of Update: 2023-02-01
According to the monitoring of the market prices of 50 important means of production in 9 categories in the national circulation field, compared with the end of December 2022, 21 products rose in price, 27 decreased, and 2 remained flat.
-
The Medical Insurance Bureau issued a "pricing mechanism" for new crown drugs: considering the cost and clinical value, but Lianhua Qingwei was not affected
Time of Update: 2023-02-01
According to the Notice, the pricing of new crown treatment drugs needs to take into account cost factors, including "raw material costs, research and development expenses, and period costs", and also fully consider "innovation" and "economy".
